ライフサイエンスコーパス: influenza vaccine

1 cts vaccinated with the monovalent 2009 H1N1 influenza vaccine.

2 accines and eventually develop a "universal" influenza vaccine.

3 o annual vaccination with seasonal trivalent influenza vaccine.

4 ration of the seasonal trivalent inactivated influenza vaccine.

5 implementation of a more broadly protective influenza vaccine.

6 s, supporting the feasibility of a universal influenza vaccine.

7 ations toward the development of a universal influenza vaccine.

8 tatin users and 60% of nonusers had received influenza vaccine.

9 hts the need to improve our current seasonal influenza vaccine.

10 oduced in addition to the seasonal trivalent influenza vaccine.

11 proven ineffective-for example, a universal influenza vaccine.

12 ose a plan for the development of an optimal influenza vaccine.

13 Most published case reports involved influenza vaccine.

14 allenge for development of a truly universal influenza vaccine.

15 ction with influenza to an inactivated whole influenza vaccine.

16 contributed to considerations of a universal influenza vaccine.

17 umans is critical to the design of universal influenza vaccines.

18 d highlighting the urgent need for universal influenza vaccines.

19 elopment of broadly protective ("universal") influenza vaccines.

20 is critical to developing effective seasonal influenza vaccines.

21 There is a need for improved influenza vaccines.

22 t for the timely release and distribution of influenza vaccines.

23 o remember the NA as we work toward improved influenza vaccines.

24 ity for consideration in the optimization of influenza vaccines.

25 bstacles in designing universal and pandemic influenza vaccines.

26 a benchmark for the development of universal influenza vaccines.

27 d the recent optimism for creating universal influenza vaccines.

28 gh 2014, with seasonal trivalent inactivated influenza vaccines.

29 ts for current seasonal and future universal influenza vaccines.

30 rmulation and standardization of our current influenza vaccines.

31 o develop improved, broadly cross-protective influenza vaccines.

32 ne the potential cardioprotective effects of influenza vaccines.

33 to exploiting these properties for improving influenza vaccines.

34 e a key challenge for the next generation of influenza vaccines.

35 n and development of more broadly protective influenza vaccines.

36 ent update for 2019-2020 northern hemisphere influenza vaccines.

37 (cIIV4), and recombinant quadrivalent (RIV4) influenza vaccines.

38 cations in development of broadly protective influenza vaccines.

39 d attention as a potent target for universal influenza vaccines(1-5).

40 ur virus strains for inclusion in the annual influenza vaccine: a type A:H1N1 virus, a type A:H3N2 vi

41 reducing the variability in responses to the influenza vaccine across the population.

42 mmunogenicity and effectiveness of different influenza vaccines across many seasons are needed.

43 than the emulsion droplet size of commercial influenza vaccine adjuvants (~160 nm).

44 files in individuals who received H5N1 avian influenza vaccine administered with MF59, with alum, or

45 za seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has

46 cing influenza vaccines.IMPORTANCE Universal influenza vaccines against the conserved epitopes of inf

47 Compared with those receiving the seasonal influenza vaccine alone, subjects receiving the pH1N1 va

48 Uptake of influenza vaccine among pregnant women remains low.

49 We analyzed the relative VE (RVE) of all influenza vaccines among Medicare beneficiaries ages >65

50 We investigated the RVE of influenza vaccines among Medicare beneficiaries ages >=6

51 on the RVE of high-dose versus standard-dose influenza vaccines among Medicare beneficiaries.

52 ly stronger CD4(+) responses compared to the influenza vaccine and thereby likely elicits better prot

53 following vaccination is a goal of universal influenza vaccines and advantageous in protecting hosts

54 Several next-generation (universal) influenza vaccines and broadly neutralizing antibodies (

55 genic mismatch between these proteins in the influenza vaccines and cocirculating influenza isolates,

56 the egg-propagated and cell culture-derived influenza vaccines and demonstrate the high-resolution s

57 nnounced a strategic plan to improve current influenza vaccines and eventually develop a "universal"

58 h are not induced by traditional inactivated influenza vaccines and may provide protection to novel v

59 effectiveness emphasizes the need for better influenza vaccines and other preventive strategies.

60 ility of negative associations between prior influenza vaccines and subsequent influenza vaccine effe

61 s offers the possibility of developing novel influenza vaccines and the feasibility for using recombi

62 ongoing efforts to increase the efficacy of influenza vaccines and to promote production strategies

63 healthy adults were vaccinated with seasonal influenza vaccine, and PBMC were collected before and up

64 on the potential cardioprotective effects of influenza vaccines, and describe the ongoing influenza v

65 n and neuraminidase from several subtypes of influenza vaccines, and utilized the existing resource t

66 ockpiled, emulsion-based adjuvanted pandemic influenza vaccines, and with demonstrated efficacy for v

67 These data suggest that influenza vaccine antigen match and dose are both import

68 escribe challenges associated with producing influenza vaccine antigens, and discuss the inherent dif

69 ed with an egg-grown adjuvanted quadrivalent influenza vaccine (aQIVe) using egg-grown target virus.

70 Universal influenza vaccines are currently being developed to elic

71 Notably, most influenza vaccines are egg propagated.

72 However, current influenza vaccines are only effective against closely ma

73 Egg-based seasonal influenza vaccines are the major preventive countermeasu

74 MF59-adjuvanted trivalent influenza vaccine (ATIV) induced distinct physiological

75 The adjuvanted trivalent influenza vaccine (aTIV) is more immunogenic than simila

76 mune responses to tetanus toxoid and subunit influenza vaccine but not, a live-attenuated viral vacci

77 r immunization with the seasonal inactivated influenza vaccine, but numbers returned to near their pr

78 re to enhance the cross-strain protection of influenza vaccine by removing the outer part of glycans

79 uenza vaccine-induced immunity might improve influenza vaccines by providing empirical evidence for o

80 ther, these findings show that an adjuvanted influenza vaccine can substantially increase antibody re

81 We argue that seasonal influenza vaccines can be dramatically improved by moder

82 we confirm that currently licensed seasonal influenza vaccines can boost preexisting memory response

83 We show that live influenza vaccines can contain underappreciated subpopul

84 ssment illustrated herein was focused on the influenza vaccine candidate H1ssF, a hemagglutinin (grou

85 Various novel influenza vaccine candidates are being evaluated in anim

86 us infection.IMPORTANCE Most current and new influenza vaccine candidates consist of a single influen

87 almost all preclinical studies evaluate new influenza vaccine candidates in immunologically naive an

88 th capacity developed within 3 large ongoing influenza vaccine cardiovascular outcomes trials to dete

89 influenza vaccines, and describe the ongoing influenza vaccine cardiovascular outcomes trials, highli

90 ason, quadrivalent, inactivated cell-derived influenza vaccine (ccIIV4) vaccine was produced using A(

91 eneficiaries aged >=65 years who received an influenza vaccine (cell-cultured, egg-based quadrivalent

92 egy for the development of a next generation influenza vaccine centers upon using conserved domains o

93 Neither influenza vaccine clearly excelled in protecting childre

94 Influenza vaccine coated onto the HD-MAP was stable stor

95 e effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with standard-dose (SD) produ

96 d randomisation list, to receive inactivated influenza vaccine containing 15 mug of each of the three

97 Germinal centre B cells that bind to influenza vaccine could be detected as early as one week

98 improvements in effectiveness or coverage of influenza vaccine could lead to substantial additional r

99 e improvements in effectiveness or VC of the influenza vaccine could lead to substantial additional r

100 be a useful therapy and that the efficacy of influenza vaccines could be enhanced by ensuring the app

101 To understand how influenza vaccines could be improved, vaccine effectiven

102 dings suggest that interventions to increase influenza vaccine coverage among pregnant women are need

103 national age-specific estimates of 2017-2018 influenza vaccine coverage and disease burden.

104 age-specific estimates of national 2018-2019 influenza vaccine coverage, influenza virus-specific vac

105 The efficacy of influenza vaccines, currently at 44%, is limited by the

106 ves were to assess the immunogenicity of the influenza vaccine delivered by HD-MAP.

107 bility, and immunogenicity of lower doses of influenza vaccine delivered by MAPs.

108 Here, we review the history of seasonal influenza vaccines, describe challenges associated with

109 uld improve an NS1-truncated live attenuated influenza vaccine developed for poultry (PC4) by selecti

110 " - are the focus of the current "universal" influenza vaccine development efforts.

111 Influenza vaccine development has largely focused on the

112 ovide broad protection is greatly needed for influenza vaccine development.

113 ed the population-level impacts of universal influenza vaccines distributed according to empirical ag

114 vaccine versus a standard-dose intramuscular influenza vaccine does not result in differences in hema

115 We used US virologic surveillance and US Influenza Vaccine Effectiveness (Flu VE) Network data to

116 To date, no study has examined influenza vaccine effectiveness (IVE) against laboratory

117 nal studies have shown decreases in measured influenza vaccine effectiveness (mVE) during influenza s

118 We sought to determine the seasonal influenza vaccine effectiveness (VE) against laboratory-

119 We estimated influenza vaccine effectiveness (VE) against mortality f

120 Here, we report influenza vaccine effectiveness (VE) and estimate the nu

121 ational studies have consistently shown that influenza vaccine effectiveness (VE) is lower for H3N2 r

122 The low influenza vaccine effectiveness (VE) observed during the

123 Influenza vaccine effectiveness (VE) varies by season, c

124 ween prior influenza vaccines and subsequent influenza vaccine effectiveness (VE), depending on seaso

125 In recent studies of influenza vaccine effectiveness (VE), lower effectivenes

126 a statistical model to data from studies of influenza vaccine effectiveness (VE), we find that prima

127 (ARI) remain as the only option to estimate influenza vaccine effectiveness (VE).

128 reduce influenza vaccine response and reduce influenza vaccine effectiveness (VE).

129 Influenza vaccine effectiveness against influenza and no

130 Recurrent reports of suboptimal influenza vaccine effectiveness have renewed calls to de

131 The US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) is a mu

132 The Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) consis

133 s-specific vaccine effectiveness from the US Influenza Vaccine Effectiveness Network, and disease bur

134 Influenza vaccine effectiveness was low in 2017-2018, ye

135 onfirmed a finding of intra-season waning of influenza vaccine effectiveness.

136 in outpatient, but not inpatient, studies of influenza vaccine effectiveness.

137 nts and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41.0% [24.1-54.1]; p<0.0001)

138 ients and 81 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74.2% [57.8-84.3]; p<0.0001)

139 We examined factors contributing to reduced influenza vaccine efficacy in the elderly and uncovered

140 asis of several current "one-shot" universal influenza vaccine efforts because they protect against a

141 inin (HA) stem has been a focus of universal influenza vaccine efforts.

142 Influenza vaccines elicit immune responses that are prot

143 Egg- and cell-derived 2018-2019 season influenza vaccines elicited similar neutralization titer

144 N2 component of the 2019 Southern Hemisphere influenza vaccine elicits an antibody response in ferret

145 As part of the Household Influenza Vaccine Evaluation (HIVE) study, acute respira

146 Avian influenza vaccines exhibit poor immunogenicity in humans

147 There are concerns that influenza vaccine exposure during pregnancy may be assoc

148 children aged 24 to 59 months with no prior influenza vaccine exposure were randomized to receive a

149 If the universal influenza vaccine field incorporates this antigen into n

150 The VE of inactivated quadrivalent influenza vaccine for preventing hospitalized influenza

151 tial to inform the design of next-generation influenza vaccines for broad and durable protection.

152 ct influenza B viruses, further complicating influenza vaccine formulation and highlighting the urgen

153 em and necessitates the annual evaluation of influenza vaccine formulation to keep pace with viral es

154 persons who were vaccinated with inactivated influenza vaccine from 1 September 2010 to 31 March 2017

155 A regimen of double-dose inactivated influenza vaccine gave slightly greater immunogenicity t

156 uenza-positive infants born to mothers given influenza vaccine had lower pneumococcal carriage rates

157 Studies have found that the high-dose influenza vaccine has a higher relative vaccine effectiv

158 ntial burden worldwide, and current seasonal influenza vaccine has suboptimal effectiveness.

159 Influenza vaccines have a long history of safety and dem

160 Current seasonal influenza vaccines have highly variable efficacy, and th

161 s were stratified into 4 groups according to influenza vaccine history (not vaccinated current and pr

162 Inactivated influenza vaccine (IIV) and pertussis vaccination are re

163 A vaccine (rHA) and cell-derived inactivated influenza vaccine (IIV) to egg-derived IIVs provide oppo

164 g antibody responses elicited by inactivated influenza vaccines (IIV), but neutralizing antibody resp

165 ystem to intramuscular trivalent inactivated influenza vaccine (IIV3) or a control of inactivated pol

166 ect effectiveness of a trivalent inactivated influenza vaccine (IIV3).

167 2017-2018, injectable, trivalent inactivated influenza vaccines (IIV3) and a nasal spray, tetravalent

168 -controlled (trivalent high-dose inactivated influenza vaccine [IIV3-HD], or quadrivalent recombinant

169 2)v vaccine and several seasonal inactivated influenza vaccines (IIVs) in adults, elderly and childre

170 2)v vaccine and several seasonal inactivated influenza vaccines (IIVs) in adults, elderly individuals

171 Human studies that reported influenza vaccine immunogenicity, effectiveness, and eff

172 ndidate for future work toward a pandemic H2 influenza vaccine.IMPORTANCE H2N2 influenza has caused a

173 ness and impact of universal T cell-inducing influenza vaccines.IMPORTANCE Universal influenza vaccin

174 ntrol study to estimate the effectiveness of influenza vaccine in children and adults with asthma in

175 were much less effective as adjuvants for an influenza vaccine in mice than the emulsion droplet size

176 tal studies of the effectiveness of seasonal influenza vaccine in older adults have found 40%-60% red

177 ntrol study to estimate the effectiveness of influenza vaccine in people with asthma in Scotland over

178 of different dosing schedules of inactivated influenza vaccine in pregnant women living with HIV in S

179 staining and compared to responses following influenza vaccine in SOT patients.

180 enuated in those reporting immunisation with influenza vaccine in the preceding three years, independ

181 onal attainment, and not having received the influenza vaccine in the prior year.

182 ithin 180 days after receiving an injectable influenza vaccine in the same arm.

183 this risk can be attenuated with the annual influenza vaccine in this patient population.

184 adults immunized with one of three types of influenza vaccines in a randomized, open-label trial dur

185 MN assay to quantify the immune response of influenza vaccines in clinical studies, particularly for

186 e to lower vaccine effectiveness of seasonal influenza vaccines in humans.

187 ficacy, effectiveness, and immunogenicity of influenza vaccines in populations within Africa with the

188 on the RVE of high-dose versus standard-dose influenza vaccines in preventing influenza-related hospi

189 MF59 adjuvant, a component in some seasonal influenza vaccines, in stockpiled, emulsion-based adjuva

190 Challenges to producing a truly universal influenza vaccine include eliciting broad protection aga

191 Several influenza vaccines include antigens that are produced th

192 Several influenza vaccines include antigens that are produced th

193 The 2019-2020 Northern Hemisphere influenza vaccine includes antigens from 3c3.A H3N2 viru

194 ulfated-N-glycan structures in large sets of influenza vaccines, including those highly branched nons

195 The RVE of high-dose versus standard-dose influenza vaccines increases with age.

196 The adjuvant (PS-GAMP) vigorously augmented influenza vaccine-induced humoral and CD8(+) T cell immu

197 tives into host-specific factors that impact influenza vaccine-induced immunity and protection.

198 onsideration of the host factors that affect influenza vaccine-induced immunity might improve influen

199 Live-attenuated influenza vaccine induces both mucosal and systemic anti

200 ndard-dose, seasonal, trivalent, inactivated influenza vaccine induces moderate-to-low haemagglutinat

201 Formulation of the seasonal influenza vaccine (injectable trivalent inactivated infl

202 Although the influenza vaccine is able to achieve serological respons

203 The seasonal influenza vaccine is an important public health tool but

204 Since it is unknown whether influenza vaccine is leaky, we simulated the 2011-2012 t

205 There is no doubt that an improved influenza vaccine is on the horizon.

206 The seasonal influenza vaccine is recommended for all persons over 6

207 Immunity generated by influenza vaccines is a complex scientific issue with ma

208 Annual vaccination with influenza vaccines is recommended for protection against

209 Seasonal influenza vaccines lack efficacy against drifted or pand

210 The effectiveness of the live-attenuated influenza vaccine (LAIV) can vary widely, ranging from 0

211 aluated a Russian-backbone, live, attenuated influenza vaccine (LAIV) for immunogenicity and viral sh

212 ic H1N1 (pH1N1) component in live attenuated influenza vaccine (LAIV) is poor.

213 Live attenuated influenza vaccine (LAIV) is recommended for annual influ

214 rent influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to eli

215 rivalent, Russian-backbone, live, attenuated influenza vaccine (LAIV) or placebo.

216 The (H1N1)pdm09 live attenuated influenza vaccine (LAIV) strain was changed for the 2017

217 Live-attenuated influenza vaccine (LAIV) was licensed for prophylaxis of

218 ort the interactions between live-attenuated influenza vaccine (LAIV), successive pneumococcal challe

219 Live-attenuated influenza vaccines (LAIV) have been shown to be effectiv

220 accine [TIV] vs. intranasal live, attenuated influenza vaccine [LAIV]) was postulated to have impacte

221 d a nasal spray, tetravalent live-attenuated influenza vaccine (LAIV4) were used in parallel in Finla

222 The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in r

223 This result suggests that cell-derived influenza vaccines may have greater effectiveness than s

224 to reduce variability in the protection that influenza vaccines offer (eg, developing vaccines that a

225 Between 2010 and 2016, influenza vaccines offered moderate protection against l

226 The protection that an influenza vaccine offers can vary significantly from per

227 Current influenza vaccines only confer protection against homolo

228 hild in each household randomized to receive influenza vaccine or placebo, for an influenza B epidemi

229 ility and improve the protective efficacy of influenza vaccines, our research group has pioneered the

230 e new insights for developing more effective influenza vaccines, particularly in older adults.

231 bstantial gaps exist in our understanding of influenza vaccine performance across all WHO high-risk g

232 edical community's understanding of seasonal influenza vaccine performance remains limited.

233 hese knowledge gaps is vital to guide future influenza vaccine policies.

234 The H3N2 component of egg-based 2017-2018 influenza vaccines possessed an adaptive substitution th

235 ven reference antigens containing HA used in influenza vaccine potency testing.

236 Seasonal influenza vaccines prevent influenza-related illnesses,

237 ral influenza infection and current seasonal influenza vaccines primarily induce neutralizing antibod

238 Multivalent influenza vaccine products provide protection against in

239 The 2016-2017 influenza vaccines provided moderate protection against

240 in BALB/c mice with inactivated quadrivalent influenza vaccine (QIV) and tested the cellular and humo

241 ction of commercially available quadrivalent influenza vaccine (QIV) containing A/Singapore/GP1908/20

242 nses to the 2017-18 inactivated quadrivalent influenza vaccine (QIV) in men living with antiretrovira

243 hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV).

244 This study evaluates the remaining effect of influenza vaccines received in the 5 prior seasons.

245 fectiveness of NS1-truncated live attenuated influenza vaccines relies heavily on their ability to in

246 AIV4 and injectable, tetravalent inactivated influenza vaccines replacing IIV3.

247 Influenza vaccines represent the most effective response

248 cent studies suggest that statins may reduce influenza vaccine response and reduce influenza vaccine

249 inistic role in the differential efficacy of influenza vaccine responses observed for various age coh

250 pture the effect of pre-existing immunity on influenza vaccine responses.

251 l (HC) participants selected from a seasonal influenza vaccine responsiveness study.

252 ccine [IIV3-HD], or quadrivalent recombinant influenza vaccine [RIV4]), safety and immunogenicity tri

253 raham pigs, using the single cycle candidate influenza vaccine S-FLU.

254 the glycosylation patterns of the 2014-2015 influenza vaccine season standard antigens A/California/

255 n Member States within the UNISEC (Universal Influenza Vaccines Secured) project.

256 iscuss the inherent difficulties of updating influenza vaccine strains each influenza season.

257 t using this antigen as the basis for future influenza vaccine strategies.

258 The goal of next-generation influenza vaccines, such as HA head-based COBRA, is to s

259 immunization with intranasal live attenuated influenza vaccine, suggesting a common role across sever

260 Seasonal and many universal influenza vaccines target the HA surface protein, which

261 FLU-v is a broad-spectrum influenza vaccine that induces antibodies and cell-media

262 ng the Vaxxas HD-MAP to deliver a monovalent influenza vaccine that was to the best of our knowledge

263 y groups are attempting to produce universal influenza vaccines that can protect across a wide variet

264 evaluation of antibodies and next-generation influenza vaccines that generate antibodies which do not

265 orts are underway to produce next-generation influenza vaccines that provide durable protection again

266 Some antiviral drugs and broadly reactive influenza vaccines that target the HA protein have suffe

267 Among current influenza vaccines, the live attenuated influenza vaccin

268 uscular (i.m.) administration of a trivalent influenza vaccine (TIV season 2012-2013) (1:1:1 ratio).

269 ferent combinations of trivalent inactivated influenza vaccine (TIV with or without adjuvant), A/H3N2

270 han similarly-dosed non-adjuvanted trivalent influenza vaccine (TIV) and observational studies sugges

271 from a young adult vaccinated with trivalent influenza vaccine (TIV), which inhibited N1 NA from viru

272 sorbent assay (ELISA) for seasonal trivalent influenza vaccine (TIV).

273 za vaccine (injectable trivalent inactivated influenza vaccine [TIV] vs. intranasal live, attenuated

274 udy 1, performed with a cell-grown trivalent influenza vaccine (TIVc) using cell-grown target virus i

275 the adjuvant MF59 has been used in seasonal influenza vaccines to increase antibody titers and impro

276 A universal influenza vaccine (UIV) could considerably alleviate the

277 Strategies to boost influenza vaccine uptake has the potential to substantia

278 Strategies to boost influenza vaccine uptake have the potential to substanti

279 r, CytoDx is able to predict the response to influenza vaccine using highly heterogeneous datasets, d

280 have shown that a standard-dose intradermal influenza vaccine versus a standard-dose intramuscular i

281 the success of HA-stalk-targeting universal influenza vaccines-viral escape from vaccine-induced sta

282 ts suggest that effectiveness of inactivated influenza vaccine wanes during the course of a single se

283 We examined whether the effectiveness of influenza vaccine wanes during the influenza season with

284 Receipt of seasonal influenza vaccine was associated with an adjusted 22% (9

285 ere was no evidence to suggest that seasonal influenza vaccine was associated with major malformation

286 In 2009, a novel influenza vaccine was distributed worldwide to combat th

287 Influenza vaccine was effective in preventing hospitaliz

288 -2011 to 2017-2018) in Canada when trivalent influenza vaccine was predominantly used.

289 Influenza vaccine was protective in 2017, yet VE was low

290 Finally, using subunit influenza vaccine, we demonstrated that daily vaccinatio

291 he small group sizes and use of a monovalent influenza vaccine were limitations of the study.

292 ed 19 years or greater, 80% were female, and influenza vaccines were most frequently reported.

293 specifically dedicated to improving seasonal influenza vaccines while developing entirely new vaccine

294 marize how aging affects the response to the influenza vaccine with a special focus on B cells, which

295 ly identified the development of a universal influenza vaccine with an efficacy of at least 75% as a

296 Compared with vaccination of the traditional influenza vaccine with complex glycosylations from eggs,

297 mpts to develop broadly protective universal influenza vaccines with durable protection are under way

298 Live attenuated influenza vaccines with truncations in nonstructural pro

299 atients on ICIs who received the inactivated influenza vaccine within ~ approximately 2 months of ICI

300 An effective H2 influenza vaccine would need to elicit broadly cross-rea